NCT05544591View on ClinicalTrials.gov

Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

July 10, 2023

Study Completion Date

September 20, 2023

Conditions
Dermatitis, Atopic
Interventions
DRUG

611 Q2W

subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)

DRUG

611 Q4W

subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)

DRUG

Matching placebo

subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles

Trial Locations (5)

100044

Peking University People's Hospital, Beijing

310003

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou

322000

The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua

330200

Dermatology Hospital of Jiangxi Province, Nanchang

510091

Dermatology Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY